Oxurion has decided to file for bankruptcy following failure of THR 149 in diabetic macular edema study.
Disappointing data from a trial of the last remaining drug in its pipeline means that Oxurion (formerly known as ThromboGenics) is closing its doors after more than 30 years
Oxurion announced on 20 November it had "decided to take the necessary steps to file for bankruptcy" on the back of disappointing topline data from part B of a Phase II trial evaluating THR 149 for diabetic macular edema (DME). In the 112-patient study, entitled KALAHARI, the plasma kallikrein inhibitor did not show improvement in vision compared with Bayer AG and Regeneron Pharmaceuticals, Inc.’s Eylea (aflibercept), the current standard of care.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins